EE9 Cost-Effectiveness Analysis of Dupilumab, Mepolizumab and Benralizumab for Severe Eosinophilic Asthma With Blood Eosinophil Count ≥300 Cells/Mcl in the Brazilian Private Healthcare Perspective
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.263
https://www.valueinhealthjournal.com/article/S1098-3015(22)02467-6/fulltext
Section Title :
Section Order :
12067
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02467-6&doi=10.1016/j.jval.2022.09.263